Cargando…

Patterns of care for older patients with stage IV non‐small cell lung cancer in the immunotherapy era

BACKGROUND: Historically, older patients with advanced lung cancer have often received no systemic treatment. Immunotherapy has improved outcomes in clinical trials, but its dissemination and implementation at the population level is not well‐understood. METHODS: A retrospective cohort study of pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kehl, Kenneth L., Hassett, Michael J., Schrag, Deborah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064091/ https://www.ncbi.nlm.nih.gov/pubmed/31989786 http://dx.doi.org/10.1002/cam4.2854

Ejemplares similares

EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?
por: Liu, Bailong, et al.
Publicado: (2021)

Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016
por: Sussman, Tamara A, et al.
Publicado: (2022)

Palliative radiation and fractionation in medicare patients with incurable non-small cell lung cancer
por: Lam, Miranda B., et al.
Publicado: (2018)

Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
por: Hurkmans, Daan P., et al.
Publicado: (2020)

Survival benefit from immunocheckpoint inhibitors in stage IV non‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis
por: Takamori, Shinkichi, et al.
Publicado: (2020)

Assessment of Temporal Selection Bias in Genomic Testing in a Cohort of Patients With Cancer
por: Kehl, Kenneth L., et al.
Publicado: (2020)

Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2020)

Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non‐small cell lung cancer
por: Zhao, Qian, et al.
Publicado: (2021)

What is the role of consolidative thoracic radiotherapy in the era of chemo-immunotherapy for extensive stage small cell lung cancer?
por: Higgins, Kristin A., et al.
Publicado: (2020)

Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non–Small Cell Lung Cancer
por: Kehl, Kenneth L., et al.
Publicado: (2021)

Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non‐small cell lung cancer
por: Deng, Jie, et al.
Publicado: (2022)

Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis
por: Woodford, Katrina, et al.
Publicado: (2022)

Real‐world outcomes of chemoradiotherapy for unresectable Stage III non‐small cell lung cancer: The SOLUTION study
por: Horinouchi, Hidehito, et al.
Publicado: (2020)

Immunotherapy for extensive stage small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
por: Assi, Hazem I., et al.
Publicado: (2023)

Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer
por: Liu, Xiaoli, et al.
Publicado: (2023)

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
por: Garrido, Pilar, et al.
Publicado: (2021)

Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer
por: Harada, Hiroaki, et al.
Publicado: (2015)

Impact of visceral pleural invasion on the association of extent of lymphadenectomy and survival in stage I non‐small cell lung cancer
por: Wo, Yang, et al.
Publicado: (2019)

Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?
por: Deslypere, Griet, et al.
Publicado: (2018)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer
por: Liew, Mun Sem, et al.
Publicado: (2013)

Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer
por: Shi, Yunfei, et al.
Publicado: (2021)

Personal and clinical characteristics associated with immunotherapy effectiveness in stage IV non-small cell lung cancer
por: Patel, Krishna H., et al.
Publicado: (2023)

Impact of Liver Metastasis on First-Line Immunotherapy in Stage IV Non-Small Cell Lung Cancer
por: Komiya, Takefumi, et al.
Publicado: (2023)

Efficacy of surgery and chemotherapy for stage IV small bowel adenocarcinoma: A population‐based analysis using Surveillance, Epidemiology, and End Result Program database
por: Liu, Tongtong, et al.
Publicado: (2020)

Serial ultra‐deep sequencing of circulating tumor DNA reveals the clonal evolution in non‐small cell lung cancer patients treated with anti‐PD1 immunotherapy
por: Li, Li, et al.
Publicado: (2019)

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
por: Deng, Jia-Yi, et al.
Publicado: (2023)

Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population‐based analysis
por: Wang, Jiwei, et al.
Publicado: (2019)

Social determinants of stage IV anal cancer and the impact of pelvic radiotherapy in the metastatic setting
por: Repka, Michael C., et al.
Publicado: (2017)

Simultaneous integrated boost of intensity‐modulated radiation therapy to Stage II‐III non‐small cell lung cancer with metastatic lymph nodes
por: Li, Qing‐Song, et al.
Publicado: (2020)

Combined Radiomics–Clinical Model to Predict Radiotherapy Response in Inoperable Stage III and IV Non-Small-Cell Lung Cancer
por: Chen, Wenrui, et al.
Publicado: (2022)

The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life
por: Park, Rebekah, et al.
Publicado: (2020)

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer
por: Wang, Shang-Jui, et al.
Publicado: (2020)

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
por: Peng, Xiao-Xiao, et al.
Publicado: (2020)

Development and validation of a nomogram predicting the overall survival of stage IV breast cancer patients
por: Li, Shunrong, et al.
Publicado: (2017)

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data
por: Navani, Neal, et al.
Publicado: (2019)

Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
por: Lammers, Austin, et al.
Publicado: (2018)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

Tumor suppressor properties of the small C-terminal domain phosphatases in non-small cell lung cancer
por: Krasnov, George S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8dnqmke1hb00ukestpm656256h